Szechtman H, Culver K, Eilam D
Department of Psychiatry and Behavioral Neurosciences, McMaster University, Ontario, Canada.
Pol J Pharmacol. 1999 Jan-Feb;51(1):55-61.
OCD was once considered a rare psychiatric disorder, but recent studies estimate that, in the general population, the lifetime prevalence of OCD is 1 to 2%, twice that of schizophrenia or panic disorder. The most common form of OCD is compulsive checking. Our studies show that the behavior of rats treated chronically with the dopamine agonist, quinpirole, meets the ethological criteria of compulsive checking in OCD; may have a similar motivational basis as compulsive checking in the human; and is partially attenuated by the anti-OCD drug, clomipramine. Thus, the behavioral changes induced by chronic treatment with quinpirole may constitute an animal model of OCD checking. Since behavioral sensitization is an associated effect of quinpirole treatment, the induction of compulsive checking by quinpirole may involve the same mechanisms as the induction of drug-induced sensitization. In this respect, we demonstrated that the MAO inhibitor clorgyline, not only prevented the development of locomotor sensitization to quinpirole, but also reversed it in sensitized rats. To the extent that the quinpirole treatment is an animal model of OCD with strong face validity, it strengthens the hypothesis that dopamine systems play a role in OCD and raises the possibility that MAO inhibitors, which are used clinically for OCD, may exert their effects by acting at the MAO inhibitor displaceable quinpirole binding site.
强迫症曾被认为是一种罕见的精神疾病,但最近的研究估计,在普通人群中,强迫症的终生患病率为1%至2%,是精神分裂症或恐慌症的两倍。强迫症最常见的形式是强迫检查。我们的研究表明,长期用多巴胺激动剂喹吡罗治疗的大鼠的行为符合强迫症中强迫检查的行为学标准;可能与人类强迫检查有相似的动机基础;并且被抗强迫症药物氯米帕明部分减弱。因此,喹吡罗长期治疗引起的行为变化可能构成强迫症检查的动物模型。由于行为敏化是喹吡罗治疗的相关效应,喹吡罗诱导的强迫检查可能涉及与药物诱导敏化相同的机制。在这方面,我们证明单胺氧化酶抑制剂氯吉兰不仅能防止对喹吡罗的运动敏化的发展,而且能在致敏大鼠中使其逆转。就喹吡罗治疗是一种具有高度表面效度的强迫症动物模型而言,它强化了多巴胺系统在强迫症中起作用的假说,并增加了临床上用于治疗强迫症的单胺氧化酶抑制剂可能通过作用于单胺氧化酶抑制剂可置换的喹吡罗结合位点而发挥作用的可能性。